证券代码：920504 证券简称：博迅生物 公告编号：2026-006 上海博迅医疗生物仪器股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 1、 审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日第四届董事会第四次会议，审议通过《关于使用闲置自有资金购买理财产品的 议案》，公司计划使用不超过人民币 7,500 万元暂时闲置的自有资金购买安全性 高、流动性好的理财产品（包括但不限于结构性存款、收益凭证等），在上述额 度内资金可以循环滚动使用，自公司第四届董事会第四次会议审议通过之日起 12 个月内有效。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置自有资金购买理财产品的公告》（公告编号：2025-010）。 2、 披露标准 根据《北京证券交易所股票上市规则》相关规定，交易的成交金额占上市公 司最近一期经审计净资产的 10%以上且超 ...

证券代码：920504 证券简称：博迅生物 公告编号：2026-007 上海博迅医疗生物仪器股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权现金管理情况 1. 审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日召开了第四届董事会第四次会议，审议通过了《关于使用闲置募集资金进行现 金管理的议案》，同意公司在确保不影响募集资金投资计划正常进行、保证募集 资金安全的前提下，公司拟使用额度不超过人民币 3,800 万元的闲置募集资金进 行现金管理，在上述额度和期限范围内资金可以循环滚动使用，自董事会审议通 过之日起 12 个月内有效，如单笔产品存续期超过前述有效期，则决议的有效期 自动顺延至该笔交易期满之日。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置募集资金进行现金管理的公告》（公告编号:2025-009）。 2. 披露标准 根据《北京证券交易所 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 因经营需要，近日上海博迅医疗生物仪器股份有限公司（以下简称"公司"） 办公地址由"上海市静安区中山北路 198 号(申航大厦)909 室"变更为"上海市 松江区泖港镇中强路 599 号"；邮政编码由"200071"变更为"201607"；公司 网址由"www.boxun.com.cn"变更为"www.shbxyl.com"。 除上述调整外，公司联系电话、电子邮箱等信息均保持不变。敬请广大投资 者留意上述变更事项。 本次变更后，公司最新的联系方式如下： 证券代码：920504 证券简称：博迅生物 公告编号：2026-005 上海博迅医疗生物仪器股份有限公司 关于变更办公地址的公告 联系电话：021-66052732 传 真：021-56303876 公司邮箱：boxun@boxun.com.cn 董事会秘书联系地址：上海市松江区泖港镇中强路 599 号 1 号楼董事会秘书 办公室 董事会秘书邮箱：yingyun@boxun.com.cn 特此公告。 上海博迅 ...

Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

2、 披露标准 证券代码：920504 证券简称：博迅生物 公告编号：2026-004 上海博迅医疗生物仪器股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 1、 审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日第四届董事会第四次会议，审议通过《关于使用闲置自有资金购买理财产品的 议案》，公司计划使用不超过人民币 7,500 万元暂时闲置的自有资金购买安全性 高、流动性好的理财产品（包括但不限于结构性存款、收益凭证等），在上述额 度内资金可以循环滚动使用，自公司第四届董事会第四次会议审议通过之日起 12 个月内有效。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置自有资金购买理财产品的公告》（公告编号：2025-010）。 根据《北京证券交易所股票上市规则》相关规定，交易的成交金额占上市公 司最近一期经审计净资产的 10%以上且超 ...

Group 1 - The stock of Boshin Bio (920504) increased by 12.53% with a turnover rate of 30.08%, and a total transaction amount of 144 million yuan, showing a volatility of 16.52% [1] - The stock was listed on the exchange due to its turnover rate reaching 30.08%, with a net buying amount of 4.727 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction of 49.8218 million yuan, with a buying amount of 27.2744 million yuan and a selling amount of 22.5474 million yuan, resulting in a net buying of 4.727 million yuan [2] Group 2 - The largest buying brokerage was Guojin Securities Co., Ltd. Shenzhen Branch, with a buying amount of 10.7214 million yuan, while the largest selling brokerage was Dongfang Caifu Securities Co., Ltd. Xinyang Dongfanghong Avenue Branch, with a selling amount of 5.8820 million yuan [2] - Detailed trading information shows the top five buying and selling brokerages, with significant buying from Guojin Securities and selling from Dongfang Caifu Securities [2]

Group 1 - The report highlights the launch of "ChatGPT Health" by OpenAI, which integrates health-related conversations and connects to electronic medical records, indicating a significant potential market for AI in healthcare [9][12] - The "Artificial Intelligence + Manufacturing" initiative aims to achieve reliable supply of core AI technologies and maintain a leading position in the industry by 2027, with specific targets including the application of 3-5 general large models in manufacturing and the creation of 100 high-quality industrial datasets [12][14] - The report identifies key sectors such as AI healthcare, AI pharmaceuticals, and AI biomanufacturing as focal points for development, proposing measures like building intelligent drug discovery platforms and smart supply chain management systems [16][12] Group 2 - The North Exchange's biopharmaceutical sector saw a weekly increase of 5.85%, with medical devices rising by 7.81%, indicating strong market performance [23][26] - Among the biopharmaceutical companies, 90.48% experienced stock price increases, with notable performers including BeiYikang (+45.1%) and XinGanjian (+10.46%) [33][34] - As of January 9, 2026, there are 15 companies in the biopharmaceutical sector awaiting approval on the North Exchange, with an average projected revenue of 424 million yuan for 2024 [34][38] Group 3 - The report emphasizes the importance of AI in enhancing drug development efficiency and supply chain management, aiming to reduce costs and time in pharmaceutical processes [16][12] - The global AI healthcare market is projected to reach approximately $26.65 billion in 2024, with a compound annual growth rate (CAGR) of 38.8% expected until 2033 [18][17] - The Chinese AI healthcare industry is expected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting significant growth potential in this sector [18][19]

证券代码：920504 证券简称：博迅生物 公告编号：2026-003 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权现金管理情况 1. 审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日召开了第四届董事会第四次会议，审议通过了《关于使用闲置募集资金进行现 金管理的议案》，同意公司在确保不影响募集资金投资计划正常进行、保证募集 资金安全的前提下，公司拟使用额度不超过人民币 3,800 万元的闲置募集资金进 行现金管理，在上述额度和期限范围内资金可以循环滚动使用，自董事会审议通 过之日起 12 个月内有效，如单笔产品存续期超过前述有效期，则决议的有效期 自动顺延至该笔交易期满之日。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置募集资金进行现金管理的公告》（公告编号:2025-009）。 2. 披露标准 根据《北京证券交易所股票上市规则》相关规定，交易的成交金额占上市公 司最近一期经审计净资产的 10 ...

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

证券代码：920504 证券简称：博迅生物 公告编号：2026-002 上海博迅医疗生物仪器股份有限公司 关于签署战略合作协议的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 协议签署概况 （一）合作背景及目的 随着生物制药、特别是合成生物学领域的迅猛发展，生物制药企业、科研机 构等对生物培养过程的精准性、自动化与智能化需求日益迫切。传统的摇床培养 及静态微生物培养方式，高度依赖人工操作与经验判断，在培养条件控制、过程 监测和结果一致性等方面面临显著挑战。实现培养过程的动态、自适应、无人化 控制与在线智能监测，已成为提升研发效率、保障工艺稳定性、加速产业转化的 关键技术瓶颈。 哈尔滨工业大学自主智能无人系统工信部重点实验室在机器视觉、自主智能 控制、多设备协同及人工智能算法等领域具备深厚的研究基础与前沿技术积累， 尤其在动态系统建模、实时视觉感知与高精度自主控制方面成果显著。这些技术 为突破生物培养过程中"黑箱操作"的现状、实现从"静态培养"到"动态智能 培养"的跨越提供了核心支撑。 本次合 ...